Abstracts Archive - Page 1981 of 2425 - ACR Meeting Abstracts

Abstract Number: 1076 • 2014 ACR/ARHP Annual Meeting
U.S. Geographic Trends in the Distribution and Treatment Practices of Juvenile Systemic Lupus Erythematosus: An Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
Jennifer M.P. Woo^1,2, Ornella J. Rullo¹, Deborah K. McCurdy³ and The CARRA Registry Investigators⁴, ¹Pediatric Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, ³Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁴Childhood Arthritis and Rheumatology Research Alliance, Durham, NC
Background/Purpose: The treatment of juvenile systemic lupus erythematosus (jSLE) often requires complex medication regimens in order to address the different disease manifestations. Despite the limited…
Abstract Number: 1074 • 2014 ACR/ARHP Annual Meeting
A Meta-Analysis of the Risk of Venous Thromboembolism in Inflammatory Rheumatic Diseases
Jason J Lee¹ and Janet E. Pope², ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²St Joseph Health Care, London, ON, Canada
Background/Purpose: We performed a meta-analysis investigating the risk of developing deep vein thrombosis (DVT) and/or pulmonary embolisms (PE) in patients with inflammatory arthritis, vasculitis, and…
Abstract Number: 1075 • 2014 ACR/ARHP Annual Meeting
Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with Systemic Lupus Erythematosus on Immunosuppressive Drugs
Candace H. Feldman¹, Jun Liu², Sarah Feldman³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Human papillomavirus (HPV) is the most common sexually transmitted disease in the US and the main cause of high-grade cervical dysplasia and cervical cancer.…
Abstract Number: 1055 • 2014 ACR/ARHP Annual Meeting
Identifying Flare in Rheumatoid Arthritis (RA): Performance of the Flare-Assessment in RA (FLARE) Questionnaire in a US Population
Elena Myasoedova¹, Cynthia S. Crowson², Bruno Fautrel³, Francis Guillemin⁴, Eric L. Matteson⁵ and Sherine E. Gabriel⁶, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁴Nancy University Hospital, Nancy, France, ⁵Rheumatology, Mayo Clinic, Rochester, MN, ⁶Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Flare is an important aspect of rheumatoid arthritis (RA) patients’ disease experience with a crucial impact on quality of life and well-being. The flare-assessment…
Abstract Number: 1054 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not ACPA, Is Associated with Disease Activity in Rheumatoid Arthritis
Daniel Aletaha¹, Farideh Alasti² and Josef Smolen³, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose To investigate the associations of rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPA) with rheumatoid arthritis (RA) disease activity.Methods We analyzed the association…
Abstract Number: 1053 • 2014 ACR/ARHP Annual Meeting
Co-Morbidity Is Associated with Disease Severity in Early Rheumatoid Arthritis
Christopher Sparks¹, Aleena Abdullah², Steven Zhao³, Cristina Estrach³ and Nicola Goodson¹, ¹Musculoskeletal Biology1, University of Liverpool, Liverpool, United Kingdom, ²Musculoskeletal biology1, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology, University Hospital Aintree, Liverpool, United Kingdom
Background/Purpose Co-morbidity has been shown to increase length of hospital stay and mortality in hospitalised patients. However, in early rheumatoid arthritis (eRA) co-morbidity may confound…
Abstract Number: 1052 • 2014 ACR/ARHP Annual Meeting
Time Trends in Comorbidities Among Patients with Rheumatoid Arthritis Compared to the General Population
Cynthia S. Crowson¹, John M. Davis III², Brittny T. Major¹, Eric L. Matteson², Terry M. Therneau³ and Sherine E. Gabriel⁴, ¹Health Sciences Research, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) related comorbidities are major determinants of morbidity and mortality. Little is known regarding the trends in these conditions. The purpose of…
Abstract Number: 1051 • 2014 ACR/ARHP Annual Meeting
Rates of Renal Remission with Immunosuppressives in Lupus Nephritis: A Systematic Review and Network Meta-Analysis
Jasvinder A. Singh¹, Ahmed Kotb², Alomgir Hossain², Amy Mudano³ and George Wells⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Ottawa, Ottawa, ON, Canada, ³Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁴Cardiovascular Resarch Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose To compare renal remission rates with immunosuppressives by performing a systematic review and network meta-analyses (NMA) of RCTs of lupus nephritis. Methods We performed…
Abstract Number: 1050 • 2014 ACR/ARHP Annual Meeting
A Role for Purinergic Receptor Signalling in Basic Calcium Phosphate Crystal-Induced Inflammation
Clare C. Cunningham¹, Emma M. Corr¹, Geraldine M. McCarthy² and Aisling Dunne¹, ¹School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland, ²Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland
Background/Purpose: Basic calcium phosphate (BCP) crystals are uniquely associated with osteoarthritis (OA). They are found in the majority of affected joints and closely correlate with…
Abstract Number: 1049 • 2014 ACR/ARHP Annual Meeting
Bioactive TGF-β Is Present on Bovine Milk-Derived Exosomes: Consequences for Patients?
Bartijn C.H. Pieters, Onno J. Arntz, Mathijs G.A. Broeren, Arjan van Caam, Peter M. van der Kraan, Marieke de Vries and Fons A.J. van de Loo, Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Development of rheumatoid arthritis (RA) is associated with different genetic and environmental factors. We postulate that cow milk could be such an environmental trigger…
Abstract Number: 1048 • 2014 ACR/ARHP Annual Meeting
Oncostatin M Suppresses Activation of IL-17/Th17 Via Suppressor of Cytokine signaling3 (SOCS3) Regulation in CD4+ T Cells
Young Ok Jung^1,2, seon Yeong Lee³, Sung Yeon Lee⁴, Mi-La Cho³ and Hea-Jin Son⁵, ¹Rheumatology dept, Internal medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea, ²Rheumatology dept, Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea, ³Rheumatism Research Center, Catholic Research Institute of Medical Science, Catholic University of Korea, Seoul, South Korea, ⁴Department of Internal Medicine, Hallym University Sacred Heart Hospital, Gyeonggi-do, South Korea, ⁵Rheumatism Research Center, Catholic Institutes of Medical Science, The Catholic University of Korea, Seoul, South Korea
Background/Purpose Oncostatin M (OSM) is a pleiotropic cytokine that belongs to the interleukin(IL)-6 group of cytokines. High level of OSM were detected in synoviums of…
Abstract Number: 1047 • 2014 ACR/ARHP Annual Meeting
Type I and II Interferon Signatures in Sjogren’s Syndrome: Contributions in Distinct Clinical Phenotypes and Sjogren’s Related Lymphomagenesis
Adrianos Nezos¹, Fotini Gravani², Efstathia K. Kapsogeorgou³, Michael Voulgarelis⁴, Haralampos M. Moutsopoulos⁴, Mary K. Crow⁵ and Clio Mavragani⁶, ¹Department of Physiology, School of Medicine, University of Athens, Athens, Greece, ²Department of Rheumatology, General Hospital of Athens "G.Gennimatas", Athens, Greece, ³Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ⁴Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ⁵Department of Medicine, Hospital for Special Surgery, New York, NY, ⁶Department of Physiology, School of Medicine, University of Athens, Athens, Greece
Background/Purpose: Both type I and II interferons (IFNs) have been implicated in the pathogenesis of Sjogren’s syndrome (SS). We aimed to explore the contribution of…
Abstract Number: 1046 • 2014 ACR/ARHP Annual Meeting
Modulatory Effect of Adiponectin on Apoptosis and Proliferation of Synovial Fibroblasts from Rheumatoid Arthritis Patients
Wei Yu¹, Wenfeng Tan² and Miaojia Zhang³, ¹Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, nanjing, China, ²Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China, ³the first affliated hospital with nanjing medical univercity, nanjing, China
Background/Purpose We previously reported that adiponectin (AD) is highly expressed in the inflammatory joint of rheumatoid arthritis (RA) patients and closely correlated with progressive bone…
Abstract Number: 1045 • 2014 ACR/ARHP Annual Meeting
Tertiary Lymphoid Organ Developmental Program: Diversgent Paradigm of Lymphoid Organogenesis
Saba Nayar¹, Bridget Glaysher², Joana Campos³, Jorge Caamano³, David Withers⁴, Kai Toellner³, Sanjiv Luther⁵, Mark Coles⁶, Christopher Buckley⁷ and Francesca Barone¹, ¹Rheumatology Research Group, University of Birmingham Research Laboratories, University of Birmingham, Birmingham, United Kingdom, ²Centre for Immunology and Infection, University of York, york, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴Infection and Immunity, University of Birmingham, Birmingham, United Kingdom, ⁵Chemin Des Boveresses 155, Losanne University, Epalinges, Switzerland, ⁶Centre for Immunology and Infection, University of York, York, United Kingdom, ⁷Rheumatology Research Group, The University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Tertiary lymphoid organs (TLOs) represent the histological hallmark of many immune-mediated inflammatory diseases. TLOs are characterized by a functional leukocyte aggregation and network of…
Abstract Number: 1044 • 2014 ACR/ARHP Annual Meeting
Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis
Trudy McGarry¹, Mary Connolly¹, Rebecca C. Coll², Avril A. B. Robertson³, Matthew A. Cooper³, Luke A. O'Neill², Douglas J. Veale¹ and Ursula Fearon¹, ¹Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ²Inflammation Research, School of Biochemistry and Immunology, Dublin, Ireland, ³The University of Queensland, Brisbane, Australia
Background/Purpose: The NLRP3 inflammasome is a multi-protein complex activated in response to environmental pathogens. This results in caspase-1-dependant cleavage of pro-IL-1β and IL-18 to their…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].